Next Article in Journal
Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?
Next Article in Special Issue
Overview of Histone Deacetylase Inhibitors in Haematological Malignancies
Previous Article in Journal
The Impact of Residual Symptoms in Major Depression
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2010, 3(8), 2441-2469; doi:10.3390/ph3082441

Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies

Roswell Park Cancer Institute, Genitourinary Program, Grace Cancer Drug Center, Buffalo, NY 14263, USA
*
Author to whom correspondence should be addressed.
Received: 16 July 2010 / Revised: 30 July 2010 / Accepted: 2 August 2010 / Published: 4 August 2010
(This article belongs to the Special Issue HDAC Inhibitors)
View Full-Text   |   Download PDF [413 KB, uploaded 4 August 2010]   |  

Abstract

Advancement in the understanding of cancer development in recent years has identified epigenetic abnormalities as a common factor in both tumorigenesis and refractory disease. One such event is the dysregulation of histone deacetylases (HDACs) in both hematological and solid tumors, and has consequently resulted in the development of HDAC inhibitors (HDACI) to overcome this. HDACI exhibit pleiotropic biological effects including inhibition of angiogenesis and the induction of autophagy and apoptosis. Although HDACI exhibit modest results as single agents in preclinical and clinical data, they often fall short, and therefore HDACI are most promising in combinational strategies with either standard treatments or with other experimental chemotherapies and targeted therapies. This review will discuss the induction of autophagy and apoptosis and the inhibition of angiogenesis by HDACI, and also pre-clinical and clinical combination strategies using these agents.
Keywords: cancer; epigenetics; epigenetic therapy; HDAC; HDAC inhibitors; apoptosis; angiogenesis; autophagy; pre-clinical; clinical trial cancer; epigenetics; epigenetic therapy; HDAC; HDAC inhibitors; apoptosis; angiogenesis; autophagy; pre-clinical; clinical trial
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Ellis, L.; Pili, R. Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies. Pharmaceuticals 2010, 3, 2441-2469.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top